J&J new data show nipocalimab reduces lupus activity in Phase 2

 The JASMINE study met the primary endpoint and key secondary and exploratory endpoints, including those indicating the potential of nipocalimab for steroid sparing

SLE is one of the most prevalent and debilitating autoantibody diseases, causing one's own immune system to mistakenly attack various tissues, which can lead to potentially life-threatening systemic organ damage

Based on these positive topline results, the company plans to initiate a Phase 3 program for nipocalimab in SLE

https://www.wvnews.com/news/around_the_web/partners/pr_newswire/subject/clinical_trials_medical_discoveries/johnson-johnson-unveils-new-data-showing-nipocalimab-is-the-first-and-only-investigational-fcrn-blocker/article_039de68a-0670-574e-876d-a9d35620bff6.html